KPTI - Karyopharm Therapeutics Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Newton,
United States
Type: Equity
KPTI price evolution
KPTI
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $85.11 | $31.39 | $53.19 | |
| Short term investments | $67.35 | $117.95 | $139.21 | |
| Net receivables | $31.78 | $37.99 | $31.08 | $26.96 |
| Inventory | $4.67 | $3.48 | $2.77 | $3.04 |
| Total current assets | $184.75 | $208.54 | $198.37 | $233.92 |
| Long term investments | ||||
| Property, plant & equipment | $3.08 | $3.8 | $4.45 | $4.88 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $5.44 | $6.09 | $6.52 | |
| Total investments | $67.35 | $117.95 | $139.21 | |
| Total assets | $189.48 | $213.98 | $204.46 | $240.44 |
| Current liabilities | ||||
| Accounts payable | $5.78 | $2.8 | $5.03 | $3.12 |
| Deferred revenue | ||||
| Short long term debt | $3.54 | $3.42 | $3.31 | |
| Total current liabilities | $61.49 | $57.62 | $65.34 | $69.48 |
| Long term debt | $264.09 | $192.09 | $173.01 | $173.71 |
| Total noncurrent liabilities | $288.5 | $308.07 | $307.17 | |
| Total debt | $195.63 | $176.44 | $177.02 | |
| Total liabilities | $349.12 | $346.12 | $373.41 | $376.64 |
| Shareholders' equity | ||||
| Retained earnings | -$1532.68 | -$1500.61 | -$1524.4 | -$1487.04 |
| Other shareholder equity | -$0.22 | -$0.6 | -$0.52 | -$0.16 |
| Total shareholder equity | -$132.14 | -$168.96 | -$136.21 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $53.19 | $136.88 | $197.44 | $89.12 |
| Short term investments | $139.21 | $142.78 | $38.16 | $163.32 |
| Net receivables | $26.96 | $47.09 | $22.5 | $12.88 |
| Inventory | $3.04 | $4.22 | $4.11 | $2.64 |
| Total current assets | $233.92 | $350.16 | $275.61 | $276.53 |
| Long term investments | $24.21 | |||
| Property, plant & equipment | $4.88 | $7.38 | $9.56 | $11.58 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $6.52 | $8.01 | $29.7 | $36.52 |
| Total investments | $139.21 | $142.78 | $38.16 | $187.54 |
| Total assets | $240.44 | $358.17 | $305.31 | $313.05 |
| Current liabilities | ||||
| Accounts payable | $3.12 | $2.77 | $1.6 | $4.45 |
| Deferred revenue | $0.3 | |||
| Short long term debt | $3.31 | $2.87 | $2.32 | $1.92 |
| Total current liabilities | $69.48 | $65.91 | $73.72 | $60.2 |
| Long term debt | $173.71 | $302.82 | $178.26 | $129.21 |
| Total noncurrent liabilities | $307.17 | $308.92 | $311.26 | $202.3 |
| Total debt | $177.02 | $179.07 | $180.58 | $131.13 |
| Total liabilities | $376.64 | $374.83 | $384.98 | $262.5 |
| Shareholders' equity | ||||
| Retained earnings | -$1487.04 | -$1343.94 | -$1178.65 | -$1069.61 |
| Other shareholder equity | -$0.16 | -$0.64 | $0.19 | $0.52 |
| Total shareholder equity | -$136.21 | -$16.66 | -$79.67 | $50.55 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $38.78 | $42.79 | $33.13 | $33.75 |
| Cost of revenue | $1.47 | $1.91 | $1.49 | |
| Gross Profit | $37.48 | $41.32 | $31.21 | $32.26 |
| Operating activities | ||||
| Research & development | $38.37 | $35.42 | $39.38 | |
| Selling, general & administrative | $31.07 | $29.55 | $30.69 | |
| Total operating expenses | $63.77 | $69.44 | $64.97 | $70.07 |
| Operating income | -$28.12 | -$33.76 | -$37.81 | |
| Income from continuing operations | ||||
| EBIT | $32.81 | -$31.41 | -$35.5 | |
| Income tax expense | $0.03 | $0.07 | $0.07 | $0.13 |
| Interest expense | -$9.55 | $8.95 | $5.88 | $6.21 |
| Net income | ||||
| Net income | -$32.07 | $23.79 | -$37.36 | -$41.84 |
| Income (for common shares) | $23.79 | -$37.36 | -$41.84 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $146.03 | $157.07 | $108.08 | |
| Cost of revenue | $4.94 | $5.21 | $2.71 | |
| Gross Profit | $141.09 | $151.86 | $105.38 | |
| Operating activities | ||||
| Research & development | $138.75 | $148.66 | $150.81 | |
| Selling, general & administrative | $131.88 | $145.4 | $126.42 | |
| Total operating expenses | $270.63 | $294.06 | $277.23 | |
| Operating income | -$129.54 | -$142.2 | -$171.85 | |
| Income from continuing operations | ||||
| EBIT | -$118.95 | -$139.93 | -$168.82 | |
| Income tax expense | $0.32 | $0.37 | $0.31 | |
| Interest expense | $23.82 | $25 | $27.14 | |
| Net income | ||||
| Net income | -$143.1 | -$165.29 | -$196.27 | |
| Income (for common shares) | -$143.1 | -$165.29 | -$196.27 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $23.79 | -$37.36 | -$41.84 | |
| Operating activities | ||||
| Depreciation | $0.09 | $0.09 | $0.08 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.41 | $4.97 | $5.18 | |
| Total cash flows from operations | -$38.5 | -$43.73 | -$18.59 | |
| Investing activities | ||||
| Capital expenditures | -$0.2 | |||
| Investments | $51.26 | $22.14 | $26.84 | |
| Total cash flows from investing | $80.68 | $51.26 | $21.94 | $26.84 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.26 | |||
| Net borrowings | ||||
| Total cash flows from financing | $40.97 | $0.26 | ||
| Effect of exchange rate | $0.01 | -$0.01 | -$0.02 | $0.09 |
| Change in cash and equivalents | $19.98 | $53.72 | -$21.8 | $8.61 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$143.1 | -$165.29 | -$124.09 | -$196.27 |
| Operating activities | ||||
| Depreciation | $0.53 | $0.62 | $0.79 | $0.97 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $21.71 | $35.4 | $29.78 | $24.41 |
| Total cash flows from operations | -$92.72 | -$149.55 | -$107.12 | -$160.23 |
| Investing activities | ||||
| Capital expenditures | -$0.12 | -$0.21 | -$0.14 | |
| Investments | $7.94 | -$104.14 | $147.55 | -$53.54 |
| Total cash flows from investing | $7.94 | -$104.26 | $141.84 | -$53.69 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.12 | $193.74 | $13.65 | $172.08 |
| Net borrowings | $60 | |||
| Total cash flows from financing | $1.12 | $193.74 | $73.65 | $172.08 |
| Effect of exchange rate | -$0.03 | -$0.49 | -$0.05 | $0.27 |
| Change in cash and equivalents | -$83.69 | -$60.56 | $108.32 | -$41.57 |
News
Fundamentals
| Market cap | $726.76M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 125.30M |
| Revenue | $148.44M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$87.48M |
| Revenue Q/Q | 7.70% |
| Revenue Y/Y | 1.77% |
| P/E ratio | -8.31 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 4.90 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.70 |
|---|---|
| ROA | -41.25% |
| ROE | N/A |
| Debt/Equity | -2.77 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.00 |
| Quick ratio | 2.93 |